Given that SQLE is overexpressed in pancreatic cancer and plays a role in tumor progression through cholesterol metabolism, targeting this enzyme with HCJ007 could lead to reduced tumor growth and improved patient outcomes. This evidence concerns the gene SQLE and pancreatic neoplasm.